Rendering of Seagen's Everett, WA, biomanufacturing facility (Graphic: Business Wire)

Pfiz­er to 'wind down con­struc­tion' of Seagen's $350M man­u­fac­tur­ing site

Pfiz­er is set to stop con­struc­tion of a man­u­fac­tur­ing fa­cil­i­ty start­ed by Seagen in Wash­ing­ton state, with af­fect­ed em­ploy­ees pos­si­bly mov­ing to oth­er fa­cil­i­ties, a spokesper­son con­firmed to End­points News.

“Af­ter care­ful eval­u­a­tion, we have made the dif­fi­cult de­ci­sion to wind down con­struc­tion of the site,” the spokesper­son said in an email. “There are ap­prox­i­mate­ly 120 em­ploy­ees who have been work­ing on the ini­tial set­up of the site that will be im­pact­ed.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.